Key facts
- Abcuro’s last known valuation is $700.0M (Feb 2025).
- It has raised $407.3M across 5 recorded rounds; the latest was Later Stage VC (Series C) ($200.0M) in Feb 2025.
- Notable investors include RA Capital Management, New Enterprise Associates, BlackRock, Foresite Capital, Samsara BioCapital — 20 tracked in total.
- Abcuro has filed 6 Form Ds with the SEC since 2016, most recently Feb 2025 ($80.0M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Abcuro
Funding rounds
5 roundsAbout Abcuro
Developer of immunomodulatory therapeutics designed for treating both autoimmunity and cancer. The company uses proprietary analysis of transcription data from human disease to identify new approaches to target key immune system compartments, enabling healthcare professionals to plan appropriate procedures for efficient treatments.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Newton, MA, United States
- Founded
- 2015
- Employees
- 55
- Website
- abcuro.com/
- Ownership
- Privately Held (backing)
Abcuro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abcuro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abcuro in its N-PORT filings yet. We sweep new filings monthly.